- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | Pharmala Biotech Holdings Inc: Pharmala Biotech loses $499,759 in fiscal Q3 | 1 | Stockwatch | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 30.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements and AGM Update | 165 | GlobeNewswire (Europe) | TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 21.07. | Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug | 1 | FierceBiotech | ||
| 21.07. | Pharmala Biotech Holdings Inc: Pharmala licenses U.S. rights to ALA-002 to Jupiter | 1 | Stockwatch | ||
| 21.07. | PharmAla licenses ALA-002 drug to Jupiter for US market | 2 | Investing.com | ||
| 21.07. | PharmAla vergibt US-Lizenz für Wirkstoffkandidat ALA-002 an Jupiter | 1 | Investing.com Deutsch | ||
| 21.07. | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | 295 | GlobeNewswire (Europe) | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 07.07. | Pharmala Biotech Holdings Inc: Pharmala completes ALA-002 GMP drug substance run | 1 | Stockwatch | ||
| 06.07. | PharmAla Biotech: PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset | 142 | GlobeNewswire (Europe) | TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and... ► Artikel lesen | |
| 20.05. | Pharmala Biotech Holdings Inc: Pharmala signs U.S. ALA-002 licensing term sheet | 3 | Stockwatch | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 739 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | Pharmala Biotech Holdings Inc: Pharmala signs definitive agreement to form SPV Restora | 1 | Stockwatch | ||
| 13.05. | PharmAla forms joint venture to develop novel MDXX molecule | 1 | Investing.com | ||
| 13.05. | PharmAla gründet Joint Venture zur Entwicklung eines neuartigen MDXX-Moleküls | 2 | Investing.com Deutsch | ||
| 13.05. | PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 | 182 | GlobeNewswire (Europe) | TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla" or the "Company"), a leader in the research, development, and manufacturing of clinical-grade... ► Artikel lesen | |
| 27.04. | Pharmala Biotech Holdings Inc: Pharmala, Aluvaris sign LOI for special-purpose vehicle | 3 | Stockwatch | ||
| 22.04. | Pharmala Biotech Holdings Inc: Pharmala Biotech loses $337,696 in Q2, grants options | 1 | Stockwatch | ||
| 21.04. | Pharmala Biotech Holdings reports Q2 results | 1 | Seeking Alpha | ||
| 21.04. | Pharmala Biotech Holdings Inc: Pharmala eyes U.S. MDMA access | 2 | Stockwatch |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 30,300 | +41,39 % | Amylyx's bet on a GLP-1 blocker pays off | ||
| QIAGEN | 37,415 | +0,93 % | Qiagen überzeugt mit Zahlen, Micron ohne neuen Ausbruch und AST SpaceMobile verfehlt die Erwartungen - BÖRSE TO GO | Ein wenig wurde an den Börsen auch zu Beginn der neuen Woche noch aufgrund nachlassender Zinssorgen aufgeatmet. Begleitet wurde dies allerdings von eher unschönen Neuigkeiten aus Nahost, welche prompt... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | -0,02 % | This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday | ||
| EVOTEC | 3,404 | -0,82 % | Evotec Aktie: Lebenszeichen aus der Totenstille - wer kauft denn da? | Die auffällige Ruhe bei der Evotec Aktie, die im letzten 4investors.de-Chartcheck im Mittelpunkt stand, ist durchbrochen. Damals lautete die Frage, ob jemand leise in die Totenstille der Biotechnologie-Aktie... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 371,25 | -1,24 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| TANGO THERAPEUTICS | 25,580 | +1,21 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,11 | +0,70 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | Generated second quarter 2026 XDEMVY- net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,000 | +2,18 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,73 | +0,33 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| BEAM THERAPEUTICS | 26,645 | -1,55 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 119,95 | -1,20 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| DISC MEDICINE | 80,28 | +0,29 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,710 | -0,55 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| ERASCA | 18,490 | +1,15 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| BB BIOTECH | 58,00 | +0,69 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.